

Mamta K Jain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8278742/publications.pdf>

Version: 2024-02-01

110
papers

4,582
citations

172457

29
h-index

110387

64
g-index

111
all docs

111
docs citations

111
times ranked

8154
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 988-994.e2.	4.4	7
2	HBV transcription and translation persist despite viral suppression in HBV&HIV co&infected patients on antiretroviral therapy. <i>Hepatology</i> , 2023, 77, 594-605.	7.3	2
3	Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study. <i>Journal of Cancer Education</i> , 2022, 37, 217-223.	1.3	1
4	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV&HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 676-688.	2.3	4
5	Low Rates of Hepatitis B Virus Treatment Among Treatment-Eligible Patients in Safety-Net Health Systems. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 360-368.	2.2	8
6	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet</i> , The, 2022, 399, 530-540.	13.7	48
7	Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109265.	3.2	1
8	A Multicomponent Intervention to Reduce Readmissions Among People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 161-169.	2.1	2
9	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
10	Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow&up. <i>Health Science Reports</i> , 2022, 5, .	1.5	2
11	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285.	5.8	15
12	Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2021, 73, e3572-e3605.	5.8	123
13	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	27.0	1,398
14	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	27.0	357
15	The risk of depression among racially diverse people living with HIV: the impact of HIV viral suppression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 645-653.	1.2	5
16	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	0
17	89976 ASSESSING PROTEIN BIOMARKERS ROLE IN CVD RISK PREDICTION IN PERSONS LIVING WITH HIV (PWH). <i>Journal of Clinical and Translational Science</i> , 2021, 5, 47-48.	0.6	0
18	Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. <i>American Journal of Gastroenterology</i> , 2021, 116, 1465-1475.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108567.	3.2	1
20	Incidence and Predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab116.	0.9	8
21	Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab334.	0.9	7
22	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV/HIV Co-infected Adults in North America. <i>Hepatology</i> , 2021, 74, 1174-1189.	7.3	11
23	Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. <i>American Journal of Gastroenterology</i> , 2021, 116, 976-983.	0.4	8
24	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	10.7	119
25	Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients With Suspected or Known Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	16
26	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults. <i>Hepatology</i> , 2020, 71, 411-421.	7.3	23
27	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. <i>American Journal of Hypertension</i> , 2020, 33, 43-52.	2.0	6
28	Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 114-123.	0.9	2
29	Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients With Suspected or Known Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, , .	5.8	75
30	Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, S591.	3.7	0
31	Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation. <i>Journal of Viral Hepatitis</i> , 2020, 27, 680-689.	2.0	15
32	Predictors for Poor Linkage to Care Among Hospitalized Persons Living with HIV and Co-Occurring Substance Use Disorder. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 406-414.	1.1	10
33	Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use Disorder. <i>Clinical Infectious Diseases</i> , 2020, 73, e1982-e1990.	5.8	0
34	Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S63-S69.	4.0	17
35	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. <i>PLoS ONE</i> , 2020, 15, e0224875.	2.5	3
36	Access to Coronavirus Disease 2019 Clinical Trials by English and Non-English Speakers Is Needed. <i>Clinical Infectious Diseases</i> , 2020, 71, 2298-2299.	5.8	1

#	ARTICLE	IF	CITATIONS
37	Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting Antiviral Period?. <i>Hepatology</i> , 2019, 69, 51-63.	7.3	45
38	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. <i>Antiviral Research</i> , 2019, 170, 104543.	4.1	32
39	THU-238-Low rates of antiviral therapy among treatment-eligible adults with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 70, e269-e270.	3.7	0
40	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 941-950.	10.7	83
41	The Editor's I on Disease Development. <i>Trends in Genetics</i> , 2019, 35, 903-913.	6.7	42
42	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 951-963.	10.7	99
43	Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis. <i>Hepatology</i> , 2019, 70, 40-50.	7.3	29
44	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	1.6	36
45	Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1356-1363.	4.4	10
46	Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 330-341.	2.1	21
47	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 746-757.	0.4	33
48	Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 1329-1338.	0.4	62
49	Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment. <i>Journal of Dual Diagnosis</i> , 2018, 14, 60-69.	1.2	7
50	The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 95-103.	3.7	20
51	2233. Hepatitis C Eradication: Who Is Being Left Behind in the HIV Population?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S660-S660.	0.9	0
52	2207. Barriers to HCV Treatment in a Safety-Net Hospital System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S651-S652.	0.9	0
53	Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection. <i>PLoS ONE</i> , 2018, 13, e0202524.	2.5	4
54	Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. <i>Clinical Trials</i> , 2017, 14, 264-276.	1.6	30

#	ARTICLE	IF	CITATIONS
55	An effectiveness study of group psychoeducation for hepatitis C patients in community clinics. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 679-685.	1.6	10
56	Missed Initial Medical Visits: Predictors, Timing, and Implications for Retention in HIV Care. <i>AIDS Patient Care and STDs</i> , 2017, 31, 213-221.	2.5	23
57	High Prevalence of Significant Co-Morbidities and Low Rates of Receiving Hepatitis C Virus Treatment among Ethnically Diverse, High Risk, Urban Safety-Net Hospital Populations in California and Texas. <i>Gastroenterology</i> , 2017, 152, S1189.	1.3	0
58	Pattern of Hepatitis B Virus (HBV) Core Antigen (HB CAG +) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV). <i>Gastroenterology</i> , 2017, 152, S1070.	1.3	1
59	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> . 2017. 4. e536-e546.	4.7	101
60	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV). <i>Gastroenterology</i> , 2017, 152, S27.	1.3	0
61	Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. <i>BMC Medicine</i> , 2017, 15, 204.	5.5	46
62	Thirty-Day Readmissions Among HIV-Infected Individuals at a Safety-Net Hospital: Predictors and Preventability. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
63	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. <i>Clinical Infectious Diseases</i> , 2016, 63, 1668-1676.	5.8	76
64	Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 156.	7.4	161
65	Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups. <i>Open Forum Infectious Diseases</i> . 2016, 3, .	0.9	9
66	Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients. <i>Journal of Community Health</i> , 2016, 41, 30-37.	3.8	5
67	An assessment of concurrent drug and alcohol use among patients seeking treatment for hepatitis C. <i>Annals of Clinical Psychiatry</i> , 2016, 28, 31-6.	0.6	6
68	Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable. <i>AIDS Patient Care and STDs</i> , 2015, 29, 465-473.	2.5	31
69	Acute and chronic immune biomarker changes during interferon/ribavirin treatment in <sc>HIV</sc>/<sc>HCV</sc> co-infected patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 25-36.	2.0	9
70	Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. <i>AIDS Patient Care and STDs</i> , 2015, 29, 329-337.	2.5	9
71	Faldaprevir and pegylated interferon α -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.	2.2	17
72	Assessment of arterial elasticity among <sc>HIV</sc>-positive participants with high <sc>CD4</sc> cell counts: a substudy of the <sc>INSIGHT</sc> Strategic Timing of AntiRetroviral Treatment (<sc>START</sc>) trial. <i>HIV Medicine</i> , 2015, 16, 109-118.	2.2	10

#	ARTICLE	IF	CITATIONS
73	The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health. PLoS ONE, 2014, 9, e106221.	2.5	59
74	An empirical study of alcohol consumption by patients considering HCV treatment. American Journal of Drug and Alcohol Abuse, 2014, 40, 484-489.	2.1	15
75	Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. Journal of Medical Virology, 2014, 86, 1507-1514.	5.0	38
76	Patient perspectives on hepatitis C and its treatment. European Journal of Gastroenterology and Hepatology, 2014, 26, 74-81.	1.6	25
77	Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. Clinical Infectious Diseases, 2014, 58, 555-563.	5.8	30
78	Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. General Hospital Psychiatry, 2013, 35, 122-128.	2.4	48
79	Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 1115-1120.	3.2	14
80	Knowledge and attitudes about hepatitis C virus (<sc>HCV</sc>) infection and its treatment in <sc>HCV</sc> monoâ€infecte and <sc>HCV</sc>/<sc>HIV</sc> coâ€infecte adults. Journal of Viral Hepatitis, 2013, 20, 708-714.	2.0	32
81	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e68152.	2.5	75
82	Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis. AIDS Patient Care and STDs, 2012, 26, 73-80.	2.5	29
83	A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. Journal of Medical Virology, 2012, 84, 1913-1919.	5.0	6
84	Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection. Clinical Gastroenterology and Hepatology, 2012, 10, 1284-1290.	4.4	15
85	A case of peritoneal histoplasmosis in a patient receiving chronic ambulatory peritoneal dialysis. Mycoses, 2012, 55, 99-100.	4.0	7
86	Rudhira/BCAS3 is a cytoskeletal protein that controls Cdc42 activation and directional cell migration during angiogenesis. Experimental Cell Research, 2012, 318, 753-767.	2.6	26
87	Treatment of Hepatitis B in HIV-Infected Persons. , 2012, , 141-149.		0
88	Serum miR-122 and Human Genomic DNA in Patients With Drug-Induced Acute Liver Failure or With Chronic Hepatitis C. Gastroenterology, 2011, 140, S-951.	1.3	0
89	Hepatitis B virus genotype G: Prevalence and impact in patients coâ€infecte with human immunodeficiency virus. Journal of Medical Virology, 2011, 83, 1551-1558.	5.0	28
90	Host-Based Ribavirin Resistance Influences Hepatitis C Virus Replication and Treatment Response. Journal of Virology, 2011, 85, 7273-7283.	3.4	14

#	ARTICLE	IF	CITATIONS
91	Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2010, 17, 208-216.	2.0	17
92	Role of ribavirin in HCV treatment response: now and in the future. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 673-683.	1.8	25
93	Pharmacotherapy of Chronic Hepatitis B in Adults: Focus on Tenofovir Disoproxil Fumarate. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1161.	0.1	0
94	Mortality in Patients Coinfected with Hepatitis B Virus and HIV: Could Antiretroviral Therapy Make a Difference?. <i>Clinical Infectious Diseases</i> , 2009, 48, 1772-1774.	5.8	12
95	Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment. <i>Journal of Infectious Diseases</i> , 2009, 200, 866-876.	4.0	7
96	Evaluation and treatment of the patient coinfecting with hepatitis B and HIV. <i>Current HIV/AIDS Reports</i> , 2008, 5, 103-11.	3.1	3
97	Biliary parasites: Diagnostic and therapeutic strategies. <i>Current Treatment Options in Gastroenterology</i> , 2008, 11, 85-95.	0.8	26
98	Gamma/Delta T-Cell Functional Responses Differ after Pathogenic Human Immunodeficiency Virus and Nonpathogenic Simian Immunodeficiency Virus Infections. <i>Journal of Virology</i> , 2008, 82, 1155-1165.	3.4	49
99	Gamma/Delta T Cell mRNA Levels Decrease at Mucosal Sites and Increase at Lymphoid Sites Following an Oral SIV Infection of Macaques. <i>Current HIV Research</i> , 2008, 6, 520-530.	0.5	13
100	Do HIV Care Providers Appropriately Manage Hepatitis B in Coinfected Patients Treated with Antiretroviral Therapy?. <i>Clinical Infectious Diseases</i> , 2007, 44, 996-1000.	5.8	38
101	Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV. <i>Aids</i> , 2007, 21, 2365-2366.	2.2	21
102	Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. <i>Journal of Hepatology</i> , 2007, 47, 527-537.	3.7	231
103	Drug-Induced Liver Injury Associated with HIV Medications. <i>Clinics in Liver Disease</i> , 2007, 11, 615-639.	2.1	29
104	Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. <i>Journal of Viral Hepatitis</i> , 2007, 14, 176-182.	2.0	58
105	Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. <i>HIV Medicine</i> , 2007, 8, 491-497.	2.2	31
106	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. <i>Antiviral Therapy</i> , 2007, 12, 531-541.	1.0	18
107	Acute bacterial cholangitis. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 113-121.	0.8	21
108	Case Report: Aminotransferase Elevation in HIV/Hepatitis B Virus Co-infected Patients Treated with Two Active Hepatitis B Virus Drugs. <i>AIDS Patient Care and STDs</i> , 2006, 20, 817-822.	2.5	14

#	ARTICLE	IF	CITATIONS
109	Changes in Mortality Related to Human Immunodeficiency Virus Infection: Comparative Analysis of Inpatient Deaths in 1995 and in 1999â€“2000. <i>Clinical Infectious Diseases</i> , 2003, 36, 1030-1038.	5.8	80
110	Gonococcal Retropharyngeal Abscess Complicated by Cervical Osteomyelitis in a Patient with Acquired Immunodeficiency Syndrome. <i>Infectious Diseases in Clinical Practice</i> , 2001, 10, 275-278.	0.3	0